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ABSTRACT 
 
Background: There is significant interest in comparing countries on many different 
indicators of social problems and policies.  Cross-national comparisons of drug 
prevalence and policies are often hampered by differences in the approach used to reach 
respondents and the methods used to obtain information in national surveys.  The paper 
explores how much these differences could affect cross-country comparisons. Methods: 
This study reports prevalence of drug use according to the most recent national household 
survey and then adjusts estimates as if all national surveys used the same methodology. 
It includes in the analysis European countries for which the European Monitoring Centre 
for Drugs and Drug Addiction provides the data, the United States, Canada, and Australia. 
Adjustment factors are based on US data. Findings: Adjusting for modality differences 
appears likely to modestly affect the rankings of countries by prevalence, but to an extent 
that could be important for comparisons. For example, general population surveys suggest 
that the US had some of the highest cannabis and cocaine prevalence rates circa 2012, but 
this is partially driven by the use of a modality known to produce higher prevalence 
estimates. This analysis shows that country rankings are partly an artifact of the mode of 
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interview used in national general population surveys. Conclusions: Our preliminary 
efforts suggest that cross-national prevalence comparisons, policy analyses and other 
projects such as estimating the global burden of disease could be improved by adjusting 
estimates from drug use surveys for differences in modality. Research is needed to create 
more authoritative adjustment factors. 
 
Keywords: survey methods; drug prevalence; cross-national comparisons; self-report 
data; general population surveys; drug misuse 
1. Introduction 
No discussion of social problems or social policy is complete today without comparisons 
with other countries. How well educated are British 15 year olds; look up their scores in 
the Program for International Student Assessment (OECD, 2016). How awful is homicide 
in America; look at UNODC’s report on World Homicide Rates (2014). It is hardly 
surprising that there is growing interest in making comparisons for drug problems as well.  
Unfortunately, there are few internationally standardized measures of drug 
prevalence available; two European-wide school surveys (the European School Survey 
Project in Alcohol and Drugs and the WHO Health Behavior in School-Aged Children) 
and, very occasionally, a general population survey (GPS) in a broader array of countries. 
Thus, several international comparisons of substance use and its consequences—
including the World Health Organization estimates of the burden of disease (Degenhardt 
and Hall, 2012)—partially rely on figures from national general population surveys. 
These general population surveys are now fairly standardized in terms of the key drug 
use questions, such as recentness of consumption (lifetime, last year, or last month) or 
type of drug used (e.g. cannabis, heroin, etc.). This gives an illusion of comparability or 
downplays methodological issues affecting cross-country comparability such as 
differences in the mode of questioning (Gowing et al., 2015; Mounteney et al., 2016).  
Prevalence surveys employ two main approaches to administer the questionnaire, 
Self-Administered Questionnaires (SAQ) and Interviewer-Administered Questionnaires 
(IAQ) and different modes of gathering information; e.g. Pencil & Paper (P&P), 
telephone-assisted and computer-assisted. Multiple studies have shown that the type of 
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interaction between interviewer and respondent affects the estimated prevalence rates for 
sensitive behaviors. For example, SAQ will produce higher rates than IAQ (Aquilino, 
1994; Bowman-Bowen and Menard, 2016; Turner et al., 1992). The specific method of 
implementation of a modality also has consequences. For example, Audio Computer 
Assisted Self Interviews (ACASI) produce higher rates than traditional Pencil and Paper 
(P&P) methods for SAQ interviews (Lessler et al., 2000; Lessler and O’Reilly, 1997; 
Turner et al., 1998).  
This paper explores how much these differences affect the comparisons that are 
reported in various studies (Gowing et al., 2015; Greenwald, 2009; MacCoun, 2011; 
Mounteney et al., 2016). The European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) is the source for most of our data, reflecting the fact that it has pioneered 
efforts to make such cross-national comparisons on a regular basis. The paper reports the 
results of a preliminary effort to normalize reported prevalence in general population 
surveys and explore how much that affects the rankings of countries.  
2. Background 
Mode of questioning affects the reporting of any behavior, but in particular, sensitive 
behaviors, such as drug use. Differences arise from variations in respondent willingness 
to report sensitive information in a particular mode (Aquilino, 1994, 1997; Beck et al., 
2002; Corkrey and Parkinson, 2002; Cox et al., 1992; Turner et al., 1992), the likelihood 
of reaching the respondent, and by catching response inconsistencies during the interview 
(Lessler et al., 2000; Wright et al., 1998).  
Modes of questioning that offer a greater prospect of confidentiality are associated 
with increased respondent willingness to report drug use. Every survey implements some 
protocols aiming at affording a higher perception of privacy to the respondents. For 
instance, sensitive information and personal details that could identify the respondent are 
often kept in separate files (Aquilino, 1997). However, respondents are rarely aware of 
these protocols and much of their willingness to disclose drug use depends on the 
anonymity granted by the method of collection. For these reasons, most of the surveys 
aiming at measuring sensitive behaviors (drug use, sexual practices, etc.) do not use an 
IAQ but a SAQ. Several studies show that SAQs report a higher estimate of drug use than 
IAQ interviews (Aquilino, 1994, 1997; Cox et al., 1992). SAQs allow researchers to give 
a higher degree of privacy to the respondent in the possibility to complete the 
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questionnaire in private and then return it in a sealed envelope. The same logic works for 
telephone interviews. Telephone surveys can be conducted through a Computer Assisted 
Telephone Interviewing (CATI) or an audio computer-assisted self-interviewing (T-
ACASI). In the CATI the computer dials the telephone number to be called and the 
interviewer reads the questions and records the respondent’s answers into the computer. 
In the T-ACASI the computer reads the question to the respondent who answers by 
pressing numbers on the touch-tone telephone; this results in higher prevalence rates 
(Corkrey and Parkinson, 2002; Turner et al., 2005). Reporting drug use to a telephone 
interviewer raises the same concern that respondents have in face-to-face surveys. P&P, 
SAQs, and T-ACASI guarantee a higher level of privacy and anonymity.  
Modern computerized SAQs – i.e. Computer Assisted Self-Interview (CASI) and 
ACASI – reduce the errors and response inconsistencies inherent in traditional P&P 
(Lessler et al., 2000; Lessler and O’Reilly, 1997; Tourangeau and Smith, 1996; 
Tourangeau and Yan, 2007; Wright et al., 1998). Computer SAQs may be programmed 
to detect and edit inconsistencies or to employ ‘skip patterns’ which avoid giving 
respondents questions that do not logically apply to them given their previous answers. 
For instance, if respondents report their last drug use more than 30 days ago they cannot 
report any drug use in the previous month (Cox et al., 1992). ACASI also allows those 
with limited reading ability to easily answer the questionnaire. Indeed the ACASI system 
administers questions that have been digitally recorded to which respondents may listen 
using headphones. Finally there is some evidence that computer SAQs may increase 
respondents’ perception of privacy and anonymity (Lessler et al., 2000; Tourangeau and 
Smith, 1996).  
Some factors – in particular age, sensitivity of the item, and recentness of the 
consumption being reported – modulate the effect of the mode of questioning in reporting 
drug use. The impact of the mode of questioning varies substantially across age, with 
teenagers more inclined to report drug use to surveys using instruments guaranteeing a 
higher level of privacy and anonymity (such as CASI rather than P&P). For instance, 
Wright et al. show the difference in reporting sensitive behaviors between a classical P&P 
and SAQ and CASI among respondents aged 12–18 and 19–34 (Wright et al., 1998). The 
19–34 group does not show significant differences in reporting alcohol use in the previous 
year (both CASI and P&P – SAQ groups report a prevalence of about 42%). In contrast, 
those using P&P – SAQ in the 12–18 group report a prevalence of 18.5%, while those 
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interviewed with CASI report a last year prevalence of alcohol use of 28.4%. Beside 
these, other factors may modulate the effect of mode of interview in reporting 
consumption of illicit drugs. These factors are in the background – such as home v school; 
the presence of another at the moment of the interview (parents or spouse); race or 
ethnicity; and level of mistrust (Aquilino, 1997; Beck et al., 2002; Schober et al., 1992; 
Wright et al., 1998). 
The effect of survey methods in disclosing sensitive behaviors decreases as the 
response moves from recent to less recent drug use. Indeed respondents are less willing 
to report drug consumption in the last month than lifetime consumption. Table 1 shows 
cocaine consumption prevalence in the last month (LMP), last year (LYP), and in life 
(LTP) according to the results presented by Turner et al., (Turner et al., 2005). Reporting 
cocaine prevalence in the last month increases threefold moving from CATI to T-ACASI 
while lifetime prevalence increases of just 1.2 times. 
Table 1. Prevalence of cocaine use among US population obtained by T-CASI and 
CATI 
Prevalence 
CATI T-ACASI 
Ratio T-ACASI/ 
CATI * 
Lifetime prevalence 17.90% 22.10% 1.2 
Last year Prevalence 2.80% 4.80% 1.7 
Last Month Prevalence 0.70% 2.10% 3.0 
Source: (Turner et al., 2005) *Authors’ calculation 
 
Similarly, survey methods granting a higher level of privacy and anonymity are 
generally more effective in disclosing stigmatized than socially acceptable behaviors. 
Table 2 reports prevalence of drug use in the last month for alcohol, marijuana, and 
cocaine using SAQ – P&P and IAQ – P&P (Turner et al., 1992). For the all three 
substances the SAQ shows higher use, with the SAQ:IAQ ratio increasing as we move 
from the least stigmatized (alcohol) to the most stigmatized substance (cocaine).  
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Table 2. Last month prevalence use of alcohol, marijuana and cocaine by mode of 
questioning 
Last Month Prevalence SAQ - P&P IAQ -P&P Ratio SAQ/ IAQ * 
Alcohol 54.78 51.86 1.1 
Marijuana 5.02 3.11 1.6 
Cocaine 1.23 0.5 2.5 
Source: (Turner et al., 1992) *Authors’ calculation 
 
3. Data and Methods 
This study attempts to standardize reported level of drug consumption by different 
surveys to explore how methods, and more specifically mode, of questioning, may affect 
cross-country comparability. It reports prevalence of drug consumption according to the 
most recent general population survey and then adjusts estimates as if all national surveys 
used the same methodology (Table A in the appendix reports year and characteristics of 
the national household survey used in these analyses). We made three standardizations in 
this analysis. First, we adjusted last month prevalence of cannabis use reported by 
national household population surveys as if surveys employed a CASI. Second, we 
adjusted last year prevalence of cannabis as if all national surveys used a SAQ – P&P. 
Finally, we standardized last year prevalence of cocaine use as if all national surveys used 
a CASI.  
Two criteria guide the inclusion of countries in the standardization. The first is 
the availability of data from national household surveys. As such, we included in the 
analysis European countries – for which the EMCDDA provides detailed information 
about levels of prevalence and metadata – the United States (SAMHSA, 2014), Australia 
(AIHW, 2014), and Canada (Health Canada, 2015). The second criterion is the 
availability of a conversion factor between surveys using a different mode of questioning. 
We considered just those countries employing survey methods for which we have been 
able to calculate a conversion factor for standardizing prevalence across countries. For 
instance, the figures below do not report data for Germany because in the last household 
survey it employed a multi-method survey (mail, phone, internet) for which the literature 
does not provide data for standardizing with other surveys.  
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To identify the relevant literature, we reviewed the most-cited scientific journals 
for the categories substance abuse and searched the databases offered by Medline and 
Google Scholar. Table B in the appendix summarizes the results of this search. Then we 
considered age, recentness, and type of substance in the elaboration. We calculated 
conversion factors from studies reporting differences in consumption for the adult 
population and not for adolescents only. Similarly, we compared the same kind of 
prevalence (LMP and LYP) and substance (cannabis and cocaine). These factors 
modulate the effect of the survey method in reporting drug use and omitting them could 
heavily bias the results. Where more than one study provided a conversion factor, we 
calculated the average.  
Table 3 shows the conversion factors used to adjust and standardize levels of 
prevalence across countries (see Tables C, D and E in the appendix for additional 
information). This study does not aim to estimate ‘true consumption’ nor to develop 
conversion ratios to make reported level of drug consumption comparable across 
countries. Respondents to drug consumption questions are likely to underreport their 
consumption (Colón et al., 2002; Harrison et al., 2007). It is common to correct this 
underreporting by adjusting estimates upward (Kilmer et al., 2011); however, willingness 
to report sensitive questions such as use of illicit drugs may vary across countries and 
time. All the adjustment factors calculated in this study are based on US data and might 
not apply to other countries. People can be more reluctant to report drug use in countries 
with a stricter enforcement of drug use than where the enforcement of illicit drugs is less 
intense. The same can be true if a country changes across years its policy and cultural 
attitude towards drugs (Chalmers et al., 2016). Beside mode of administration other 
characteristics of national surveys can affect reporting and estimated level of prevalence. 
These include sampling procedures, setting of the interview, use of incentives, response 
rate, and wording (Bowman-Bowen and Menard, 2016). Finally, studies used for the 
elaboration of the adjustment ratios can use different research design. For instance, they 
can use different sampling and weighting procedures or have a different ethnic 
composition of the sample.  
It is currently impossible to account for the impact of all these methodological 
and cultural variations. Adjusting for differences in survey modality can make country 
data more comparable but other factors – setting, negative attitudes towards drug taking, 
etc. – can still affect the accuracy of responses to drug-use surveys. This study is just a 
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first attempt to look into the effect that mode of questioning can have on cross-country 
comparison. It standardizes reported prevalence to explore how much that affects the 
rankings of countries. Readers should not focus on adjusted levels of prevalence but on 
differences in the rankings between un-adjusted and adjusted figures 
Table 3. Conversion factors for survey methods.  
 Cannabis LMP* Cannabis LYP** Cocaine LYP*** 
 (CASI) (P&P - SAQ) (CASI) 
P&P - SAQ 1.16 a   
ACASI 0.72 b 0.9 c 0.5 b 
CAPI 1.19 b  1.4 b 
CATI  1.63 d  
P&P - IAQ  1.26 d e f  
*Conversion factors used for Figure 1;** Conversion factors used for Figure 2;*** Conversion 
factors used for Figure  
Sources: a Wright et al., 1998; b Tourangeau and Smith, 1996; c Lessler et al., 2000; d Aquilino, 
1994; e Schober et al., 1992; f Turner et al., 1992 
4. Results  
Figure 1 A reports, in descending order, prevalence of consumption of cannabis 
in the last month for eight countries, as reported by surveys that used a variety of methods: 
ACASI, P&P – SAQ, CASI, and Computer Assisted Personal Interviewing (CAPI). 
Figure 1 B adjusts the level of prevalence reported on Figure 1 A, as if all the countries 
employed a CASI in their national household surveys, according to the conversion factors 
presented in Table 3. Although the correlation among unadjusted and adjusted prevalence 
rates is high (r = .877 and Spearman’s rank correlation (r s) = .928), there are some 
important differences. After the standardization, the US moves from first to third ranked 
for last month cannabis prevalence. In Figure 1 B, Spain exceeds by far Australia and the 
US for cannabis consumption.  
Figure 2 A reports levels of cannabis prevalence in the last year for eleven 
countries employing ACASI, P&P – SAQ, CATI, and P&P – IAQ systems in their 
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national surveys. Figure 2 B adjusts these values as if all the national household surveys 
were carried out with a traditional P&P – SAQ. Figure 2 B shows several differences in 
the rank compared to Figure 2 A (r = .862; r s = .936). Countries employing a CATI 
system, Canada, France, and Norway, shift upwards with France moving from the second 
to the first position just before Canada. The US stands in third position. Canada, Norway, 
and Belgium shift one position in the distribution.  
Figure 3A reports cocaine prevalence in the last year for the US (ACASI), UK 
(CASI), Netherlands (CASI), Ireland (CAPI), and Portugal (CAPI), and Figure 3B adjusts 
these estimates as if all the surveys were carried out with a CASI system. Figure 3B shows 
that, after adjusting for the conversion factor, Ireland (2.1%) reports almost the same 
prevalence as the neighboring UK (2.4%). Similarly, the US shows a level of 
consumption lower than the Netherlands. 
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Figure 1 A. Last month prevalence of cannabis use by National Household 
Population Surveys 
 
Figure 1 B. Adjusted last month prevalence of cannabis use. Standardization 
as CASI. Change in country’s rank in brackets 
 
Figure 2 A. Last year prevalence of cannabis use by National Household 
Population Surveys 
 
Figure 2 B. Adjusted last year prevalence of cannabis use. Standardization as 
SAQ – P&P. Change in country’s rank in brackets 
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Figure 3 A. Last year prevalence of cocaine use by National Household 
Population Surveys 
 
 
Figure 3 B. Adjusted last year prevalence of cocaine use by National 
Household Population Surveys. Standardization as CASI. Change in country’s 
rank in brackets
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5. Discussion 
It is not uncommon to find popular media sources announcing “Country X top world 
consumer of drug Y” (Lee, 2014; Smith, 2015; Travis, 2016). These league tables of drug 
prevalence are not restricted to the media but also sometimes appear in scientific papers 
(Mounteney et al., 2016; Zobel and Götz, 2011). This analysis shows that country 
rankings are partly an artifact of the mode of interview. The methods of contacting 
respondents and the technology for questioning respondents in household surveys 
complicate cross-country comparisons. For instance, Figure 1 A, Figure 2 A, and Figure 
3 A show that using unadjusted general population surveys, the United States has the 
highest prevalence rates for several indicators of drug prevalence. The analysis shows 
that this result may partially reflect that the US employs a modality (ACASI) that is 
known to produce higher estimates for a given population. Differences can seem modest 
but our comparison is limited to a small subset of countries driven by the availability of 
data.  
Bigger differences can emerge if this exercise is extended to several countries. 
Research also suggests that survey differences can in particular affect the cross-country 
comparison of the most useful drug prevalence measures for policy analysis. Survey 
mode has little impact on life-time prevalence, a measurement that is of little use for 
policy purpose since it might refer to people who consumed drug many years ago. Past-
month prevalence, a measure often used to estimate the number of regular drug users, is 
much more influenced by instruments guaranteeing a higher level of privacy and 
anonymity in the survey. The effect of survey modality can then be negligible when 
comparing generational dynamics of drug taking but can considerably affect the 
comparison of current (LYP) and regular (LMP) drug use across countries. Similarly, the 
influence of survey differences can be limited for more socially acceptable drugs (e.g. 
cannabis) than for highly stigmatized substances (e.g. cocaine). The good news is that it 
is possible to improve comparability. Our analysis was just a demonstration of the effect 
that survey differences can have on cross-country comparisons of drug use prevalence. 
We cannot conclude that our adjustment made drug use measures more comparable as 
the conversion factors rely primarily on data from US surveys. We suggest, instead, that 
more studies on the impact of survey modality should be carried out across different 
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countries. Data from different settings can produce more precise and authoritative 
adjustment factors to make drug use prevalence comparable across countries. 
Almost as serious a problem is the fact that nations sometimes change methods in 
successive surveys. The Netherlands, Germany, Italy, and Australia have all made 
changes in modality. This leaves them with two options: an inability to determine trends 
in drug use across years or forcing a comparison among surveys employing a different 
methodology. This study offers an alternative, showing how it would be possible to 
roughly estimate the extent to which variation across years is due to actual differences in 
in the level of consumption or to a shift in the methodology. For instance, between 2005 
and 2009 the Netherlands shifted from CAPI to CASI. This, as the EMCDDA (2016) and 
the Dutch Focal Point (2015) report, precluded the determination of trends between 2005 
and 2009. We can use the parameter reported in Table 3 to adjust the 2009 estimates and 
elaborate a possible scenario on how cannabis prevalence evolved (assuming for the 
moment that the Dutch and US adjustment factors are similar; this may not be correct). 
The reported data from the two surveys suggest that cannabis prevalence increased as last 
month prevalence rises from 3.3% in 2005 to 4.2% in 2009. After the correction for 
methodological change, last month cannabis prevalence in 2009 drops to 3.5, showing a 
very small change compared to 2005 and a much smaller change between 1998 and 2009 
(1998 = 3.0; 2001 = 3.4). 
The coverage of the population also varies across countries. Age range is an 
important factor defining target population. Most European countries follow the 
EMCDDA recommendation and restrict coverage to the group age 15–64 (see Table a in 
the appendix). Australia (14+), Canada (15+), Denmark (16+), and the United States 
(12+) do not provide an upper age limit while the lower limit varies between 12 (Greece 
and the United States), and 18 (Germany). Countries can easily adjust prevalence 
estimates to the group 15–64 when collecting data for broader ranges. For some countries, 
(e.g. Germany, UK, etc.), however, the targeted age group is narrower. For these countries 
the EMCDDA does not make any adjustment (personal communication with Jane 
Mounteney).  
Differences across countries in the number of institutionalized people may also 
affect cross-country comparability. While all surveys exclude the imprisoned population, 
that is a much more important exclusion for the United States than for any Western 
European country, since the incarceration rate in the US (ca. 700 per 100,000) is about 
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seven times that for most EU member states (Walmsley, 2016). Since the incarcerated 
population has a higher rate of drug use (particularly frequent use), estimates of, for 
example, lifetime cocaine use among 15–34 year olds will be under-estimated to a greater 
extent in the US than in other countries. Still other factors – sampling, setting of the 
survey (house v school), question wording, etc., – may affect the reporting of drug use to 
surveys (Bowman-Bowen and Menard, 2016). 
The issue of cross-country comparability is not limited solely to drug use 
prevalence but affects also other drug-related indicators, such as mortality, the burden of 
disease, and treatment penetration (Kilmer et al., 2015). Cross-country comparisons are 
possible but need care in interpretation. International surveys should be privileged over 
national household surveys for identifying main patterns. Comparisons of national 
surveys should explicitly take account of modality and adjust for targeting the same age 
group, and when possible be cross-checked with other sources.  
Ignoring these differences and how they can influence cross-country comparisons 
may lead to incorrect inferences and misinterpretation of the effect of drug policies.  The 
good news is that so far the effects have been modest. 
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Supplementary materials  
Table d. Year and characteristics of national household surveys used in comparisons 
Country Year Age 
range 
Data collection 
procedure(s) 
Sample 
size 
Response 
rate (%) 
Australia 2013 14+ SAQ - D&Ca 23,855 49.1% 
Austria 2008 15-93 IAQ – P&P 3761 34% 
Belgium 2013 15-64 SAQ – P&P   
Canada 2012 15+ CATI 11,090 39.8% 
Denmark 2013 16+ SAQ – Mailb 10470 61% 
Finland 2010 15-69 SAQ – Mailb 1873 48% 
France  2014 15-85 CATI 13488  
Germany 2012 18-64 MM c 9084 54% 
Greece 2004 12-64 IAQ – P&P 4351  
Ireland 2010/11 15-64 CAPI 5128  
Italy 2014 15-74 SAQ – Mail 6590  
Netherland 2014 15-64 CASI   
Norway 2013 16- 79 CATI 1794  
Portugal 2012 15-74 CAPI 5355 52% 
Spain 2013 15-64 SAQ – P&P 23136 94% 
Sweden 2014 16-84 SAQ – Mail 6523  
United States 2013 12+ ACASI 67,838 71.7% 
UK - England and 
Wales  
2014 16-59 CASI 21691  
a D&C: Drop and collect 
b
 Respondents have also the possibility to complete a web-questionnaire 
c
 Multi method: Mail, phone, Internet
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Table e. Prior studies on the effect of modality choice on reporting drug use 
Study Age range Comparison Country Drugs Prevalence 
Beck et al., 2002 15-19 SAQ-
P&P CATI   France Cannabis LYP 
Lessler et al., 2000 12-17; 18+; 12+ SAQ-
P&P ACASI   USA Tobacco, cannabis, Alcohol, cocaine LTP, LYP, LMP 
Wright et al., 1998 12-18; 12-34; 19-34 SAQ-
P&P CASI   USA Tobacco, cannabis, Alcohol LMP, LTP 
Corkrey and 
Parkinson, 2002 
18+ CATI Hybrid I Hybrid II T-ACASI Australia Alcohol, cannabis, amphetamines, heroin 
LTP, LYP, LMP, age 
of onset 
Turner et al., 2005 18-45 CATI T-ACASI   USA Alcohol, Cannabis, Cocaine, Injecting drugs LTP, LYP, LMP, L3YP 
Spijkerman et al., 
2009 
15-64 Web CASI   Netherlands Alcohol, Cannabis, Ecstasy, Cocaine, Performance enhancing drugs LTP, LYP 
Turner et al., 1992 12+ SAQ-
P&P IAQ-P&P   USA Alcohol, Cannabis, Cocaine LTP, LYP, LMP 
Aquilino, 1994 18-45 SAQ-
P&P IAQ-P&P CATI  USA Alcohol, Cannabis, Cocaine LTP, LYP, LMP 
Turner et al., 1998 15-19* ACASI SAQ-P&P   USA Alcohol, Cannabis, Cocaine, Injecting drug LTP, LYP, LMP, L3YP 
Tourangeau and 
Smith, 1996 
18-45 CAPI CASI ACASI  USA Cannabis, Cocaine LTP, LYP, LMP 
Lessler and O’Reilly, 
1997 
12-20 SAQ-
P&P CAPI ACASI  USA Alcohol, Cannabis, Cocaine LTP, LYP, LMP 
Aquilino, 1997 18-45 SAQ-
P&P IAQ-P&P CATI  USA Cannabis, cocaine, pills, any illicit drugs LTP 
Schober et al., 1992 14-21 SAQ-
P&P 
IAQ-
P&P(b) 
IAQ-
P&P(a)  USA Cannabis, Cocaine LTP, LYP, LMP 
Beebe et al., 1998 +12 students CASI P&P   USA Alcohol, Cannabis, cocaine, LSD, Amphetamines  LYP 
Knapp and Kirk, 2003 Undergraduate 
students 
SAQ-
P&P Web CATI  USA Cannabis LTP 
Note: this table reports studies on the effect that survey modality can have on reporting illicit drugs use.  It does not include studies on the effect that mode of questioning can have on other 
sensitive questions (abortion, sexual partners, etc.).  
L3YP: last three year prevalence; (a) private (b) non-private *Just males
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Table f. Studies and data used for the elaboration of the conversion factor in Figure 1* 
Study CASI (Prevalence %) 
Comparison Ratio Survey modality Prevalence (%) 
Wright et al., 1998 11 P&P - SAQ 9.5 1.16 
Tourangeau and Smith, 
1996 12.5 
ACASI 17.4 0.72 
CAPI 10.5 1.19 
* Last month prevalence for cannabis 
 
Table g. Studies and data used for the elaboration of the conversion factor in Figure 2* 
Study P&P - SAQ (Prevalence %) 
Comparison Ratio Survey modality Prevalence (%) 
Lessler et al., 2000 8.6 ACASI 9.5 0.9 
Aquilino, 1994 13 CATI 8 1.63 P&P - IAQ 10 1.28# 
Schober et al., 
1992 23.5 P&P - IAQ 19.5 1.21
#
 
Turner et al., 1992 8.64 P&P - IAQ 6.63 1.30# 
* Last year prevalence for cannabis 
# The conversion factor is given by the average of these ratios  
 
Table h. Studies and data used for the elaboration of the conversion factor in Figure 3* 
Study CASI (Prevalence %) 
Comparison Ratio Survey modality Prevalence (%) 
Tourangeau and 
Smith, 1996 2.6 
ACASI 5.4 0.5 
CAPI 1.9 1.4 
*Last year prevalence for cocaine  
 
